Coalition Resilient Outcomes in Max k-Cut Games

We investigate strong Nash equilibria in the \emph{max $k$-cut game}, where we are given an undirected edge-weighted graph together with a set $\{1,\ldots, k\}$ of $k$ colors. Nodes represent players and edges capture their mutual interests. The strategy set of each player $v$ consists of the $k$ colors. When players select a color they induce a $k$-coloring or simply a coloring. Given a coloring, the \emph{utility} (or \emph{payoff}) of a player $u$ is the sum of the weights of the edges $\{u,v\}$ incident to $u$, such that the color chosen by $u$ is different from the one chosen by $v$. Such games form some of the basic payoff structures in game theory, model lots of real-world scenarios with selfish agents and extend or are related to several fundamental classes of games. Very little is known about the existence of strong equilibria in max $k$-cut games. In this paper we make some steps forward in the comprehension of it. We first show that improving deviations performed by minimal coalitions can cycle, and thus answering negatively the open problem proposed in \cite{DBLP:conf/tamc/GourvesM10}. Next, we turn our attention to unweighted graphs. We first show that any optimal coloring is a 5-SE in this case. Then, we introduce $x$-local strong equilibria, namely colorings that are resilient to deviations by coalitions such that the maximum distance between every pair of nodes in the coalition is at most $x$. We prove that $1$-local strong equilibria always exist. Finally, we show the existence of strong Nash equilibria in several interesting specific scenarios.Comment: A preliminary version of this paper will appear in the proceedings of the 45th International Conference on Current Trends in Theory and Practice of Computer Science (SOFSEM'19

Overcoming job demands to deliver high quality of care in the hospital setting across Europe: the role of teamwork and positivity

Health care professionals deal on a daily basis with several job demands – emotional, cognitive, organizational and physical. They must also ensure high quality care to their patients. The aim of this study is to analyse the impact of job demands on quality of care and to investigate team (backup behaviors) and individual (positivity ratio) processes that help to shield that impact. Data was collected from 2,890 doctors and nurses in 9 European countries by means of questionnaires. Job demands have a negative impact on the quality of care delivered by health professionals. Backup behaviors had a mediating effect between job demands and quality of care. Also, the positivity ratio of professionals (ratio of positive and negative emotions experienced) was also found as a significant mediator between most job demands and quality of care dimensions. Finally, we found a double mediation between most job demands and quality of care, where backup behaviors influenced the positivity ratio. Quality of care in hospitals is closely related to job demands. Hospital managers should consider the importance of cooperation within health care professionals’ teams and ought to find ways to develop teamwork in order to promote patients’ safety

On a Simple Hedonic Game with Graph-Restricted Communication

International audienceWe study a hedonic game for which the feasible coalitions are prescribed by a graph representing the agents' social relations. A group of agents can form a feasible coalition if and only if their corresponding vertices can be spanned with a star. This requirement guarantees that agents are connected, close to each other, and one central agent can coordinate the actions of the group. In our game everyone strives to join the largest feasible coalition. We study the existence and computational complexity of both Nash stable and core stable partitions. Then, we provide tight or asymptotically tight bounds on their quality, with respect to both the price of anarchy and stability, under two natural social functions, namely, the number of agents who are not in a singleton coalition, and the number of coalitions. We also derive refined bounds for games in which the social graph is restricted to be claw-free. Finally, we investigate the complexity of computing socially optimal partitions as well as extreme Nash stable ones

CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies

CAR T cells targeting CD19 provide promising options for treatment of B cell malignancies. However, tumor relapse from antigen loss can limit efficacy. We developed humanized, second-generation CAR T cells against another B cell–specific marker, B cell activating factor receptor (BAFF-R), which demonstrated cytotoxicity against human lymphoma and acute lymphoblastic leukemia (ALL) lines. Adoptively transferred BAFF-R-CAR T cells eradicated 10-day preestablished tumor xenografts after a single treatment and retained efficacy against xenografts deficient in CD19 expression, including CD19-negative variants within a background of CD19-positive lymphoma cells. Four relapsed, primary ALLs with CD19 antigen loss obtained after CD19-directed therapy retained BAFF-R expression and activated BAFF-R-CAR, but not CD19-CAR, T cells. BAFF-R-CAR, but not CD19-CAR, T cells also demonstrated antitumor effects against an additional CD19 antigen loss primary patient–derived xenograft (PDX) in vivo. BAFF-R is amenable to CAR T cell therapy, and its targeting may prevent emergence of CD19 antigen loss variants

A palaeoenvironmental reconstruction (based on palaeobotanical data and diatoms) of the Middle Pleistocene elephant (Palaeoloxodon antiquus) butchery site at Marathousa, Megalopolis, Greece

Bioarchaeolog

Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma

Antibody engineering can tailor the design and activities of therapeutic antibodies for better efficiency or other advantageous clinical properties. Here we report the development of ISB 1442, a fully human bispecific antibody designed to re-establish synthetic immunity in CD38+ hematological malignancies. ISB 1442 consists of two anti-CD38 arms targeting two distinct epitopes that preferentially drive binding to tumor cells and enable avidity-induced blocking of proximal CD47 receptors on the same cell while preventing on-target off-tumor binding on healthy cells. The Fc portion of ISB 1442 is engineered to enhance complement dependent cytotoxicity, antibody dependent cell cytotoxicity and antibody dependent cell phagocytosis. ISB 1442 thus represents a CD47-BsAb combining biparatopic targeting of a tumor associated antigen with engineered enhancement of antibody effector function to overcome potential resistance mechanisms that hamper treatment of myeloma with monospecific anti-CD38 antibodies. ISB 1442 is currently in a Phase I clinical trial in relapsed refractory multiple myeloma